Drug Overview

Larotaxel (also known by its developmental code XRP9881) is a semi-synthetic taxane derivative currently utilized in clinical research for the treatment of various solid tumors. As a member of the taxane family, it is a type of Targeted Therapy that specifically interferes with the internal structure of cancer cells to stop them from multiplying.

What makes larotaxel significant in modern oncology is its improved chemical structure compared to older drugs in its class. It was designed to remain active in the body longer and to bypass certain “pumps” that cancer cells use to spit out medicine. This makes it a potential option for cancers that have become resistant to standard chemotherapy.

Generic Name: Larotaxel
US Brand Names: None (Currently an investigational drug)
Drug Class: Taxane; Microtubule Stabilizing Agent
Route of Administration: Intravenous (IV) Infusion
FDA Approval Status: Investigational (Not yet FDA approved for general use)

What Is It and How Does It Work? (Mechanism of Action)

To understand how larotaxel works, imagine a cell is like a tent. To stand up and grow, the tent needs poles. In a cell, these “poles” are called microtubules. When a cell wants to divide into two new cells, it must take these poles down and move them.

At the molecular level, larotaxel stops cancer through the following steps:

Binding to Tubulin: Larotaxel enters the cancer cell and binds specifically to beta-tubulin subunits. These are the building blocks of the microtubules.
Hyper-stabilization: Unlike many drugs that break things, larotaxel makes the microtubules too strong. It “freezes” the tent poles in place so they cannot be taken down.
Mitotic Arrest: Because the microtubules are frozen, the cell cannot move its DNA to create a new cell. The cell gets stuck in a middle phase of division called Mitosis.
Apoptosis (Cell Death): When the cell realizes it is stuck and cannot divide properly, it sends a signal to destroy itself. This is called programmed cell death.

Larotaxel is specifically designed to be less affected by the P-glycoprotein (P-gp) efflux pump. In many resistant cancers, this pump acts like a security guard that throws the medicine out of the cell. Larotaxel “hides” from this guard, staying inside the cell longer to do its work.

FDA-Approved Clinical Indications

As an investigational drug, larotaxel is not yet approved for general prescription. It is currently being studied for several specific cancer types.

Oncological Uses (Investigational)

Breast Cancer: Studied for patients whose cancer has returned after other treatments.
Bladder Cancer: Researched for advanced or metastatic transitional cell carcinoma.
Pancreatic Cancer: Investigated as part of a combination therapy.
Prostate Cancer: Studied for hormone-refractory cases.

Non-Oncological Uses

There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Larotaxel is given as a clear liquid through a needle into a vein. It must be administered by a trained medical professional in a hospital or clinic.

Protocol	Standard Investigational Guidance
Typical Dose	$60\text{ mg/m}^2$ to $90\text{ mg/m}^2$ (based on body surface area)
Frequency	Once every 3 weeks (21-day cycle)
Infusion Time	Usually delivered over 1 hour
Pre-medication	Steroids and antihistamines are given to prevent allergic reactions

Dose Adjustments:

Hepatic (Liver) Insufficiency: The liver breaks down this drug. If liver enzymes (like Bilirubin) are high, the dose must be significantly reduced or stopped to prevent toxic buildup.
Renal (Kidney) Insufficiency: Standard doses are usually allowed, but doctors monitor kidney function closely during each cycle.

Clinical Efficacy and Research Results

Recent clinical data (2020–2025) has focused on how larotaxel helps patients who no longer respond to older taxanes like Docetaxel.

Breast Cancer Results: In Phase II trials, larotaxel showed an Objective Response Rate (ORR) of approximately 35% to 42% in patients with metastatic breast cancer who had previously failed other therapies.
Disease Progression: Numerical data suggest a Median Progression-Free Survival (PFS) of roughly 4.4 months in advanced bladder cancer trials.
Resistance Management: Research confirms that larotaxel is effective in “taxane-resistant” cell lines, meaning it can kill cancer that other drugs in its class cannot.

Safety Profile and Side Effects

Black Box Warning:

None. (As an investigational drug, a formal Black Box has not been issued, but similar taxanes carry warnings for Severe Neutropenia and Severe Allergic Reactions).

Common Side Effects (>10%)

Neutropenia: A drop in white blood cells, which increases the risk of infection.
Alopecia: Temporary hair loss.
Fatigue: Feeling unusually tired or weak.
Nausea/Vomiting: General stomach upset.

Serious Adverse Events

Peripheral Neuropathy: Numbness, tingling, or pain in the hands and feet.
Hypersensitivity: Severe allergic reactions (shortness of breath, swelling).
Febrile Neutropenia: A fever occurring when white blood cells are dangerously low.

Management Strategies

For Low White Cells: Doctors may use “growth factor” injections (like G-CSF) to help the bone marrow recover.
For Allergic Reactions: Patients are closely watched during the first 15 minutes of the drip. If a reaction happens, the drip is stopped immediately.

Research Areas

Larotaxel is a primary subject in Combination Immunotherapy research. Scientists are exploring if larotaxel can “unmask” a tumor. By killing some cancer cells and causing them to burst, the drug releases tumor markers into the blood. This helps the immune system—and other drugs like Checkpoint Inhibitors– find and attack the remaining cancer. Additionally, there is early research into using larotaxel in Nanoparticle delivery systems to send the drug directly to the tumor while avoiding healthy tissues.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Complete Blood Count (CBC): To ensure white blood cells are high enough for treatment.
Liver Function Test (LFT): To check how well the liver is working.
Neurological Exam: To check for existing numbness or tingling in the hands/feet.

Precautions During Treatment

Infection Risk: Avoid large crowds and people who are sick, as your body cannot fight germs as well.
Contraception: This drug can harm an unborn baby. Use highly effective birth control during and for several months after treatment.

“Do’s and Don’ts” List

Do: drink plenty of water to help your body flush out the medicine.
Do report any fever over $38^\circ\text{C}$ ($100.4^\circ\text{F}$) to your doctor immediately.
Don’t take new herbal supplements (like St. John’s Wort) without asking your oncologist, as they can interfere with the drug.
Don’t ignore “pins and needles” feelings in your fingers; tell your medical team early.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Larotaxel is an investigational medication. Always consult with a licensed oncologist or healthcare professional regarding your specific diagnosis and treatment options. This content reflects clinical data available as of early 2026.